OSLO, NORWAY--(Marketwired - April 12, 2013) - Algeta ASA (OSE: ALGETA), a company focused on
development of novel targeted cancer therapeutics, is very pleased to
that Mrs Hilde Furberg and Mr Paolo Pucci were elected as new Non-executive
members of its Board of Directors at the Company's annual general meeting
in Oslo on 11 April 2013.
Hilde Furberg (born 1958) has 30 years of experience in the
industry. She is currently Senior Vice President Rare Disease EMEA at
(Sanofi), which she joined in 2002. She opened the first operation for
in the Nordic region and has also had management responsibility for
the BeneLux region. Prior to Genzyme, Mrs Furberg spent 15 years at
various business roles of increasing seniority. She is a Non-executive
on the Board of Clavis Pharma ASA and is a board member of Copenhagen
Previous board memberships include Probi AB and Pronova Biopharma ASA
acquisition by BASF).
Mrs Furberg holds a Master of Science degree in Nuclear Analytical
from the University of Oslo. She is a Norwegian citizen and resides
Mrs Furberg holds 200 shares and no options in Algeta ASA and she has not
as a consultant for the Company.
Paolo Pucci (born 1961) is Chief Executive Officer and member of the
Directors of ArQule Inc., a US-based, Nasdaq-listed cancer therapeutics
which he joined in 2008. Before this, Mr Pucci was at Bayer AG, where he
sequential responsibilities as Country Head Bayer Italy
President & SVP Bayer Pharmaceuticals North America - Global
Pharmaceuticals, and member of the Bayer Pharmaceuticals Executive
concluded his tenure at Bayer as President in charge of the Bayer-
Pharmaceuticals Global Oncology/Specialized Therapeutics Business Units
instrumental in building Bayer's global oncology franchise for
to this, Mr Pucci held positions of increasing responsibility with Eli
between 1992 and 2001, culminating with his appointment as Managing
Eli Lilly Sweden AB. Mr Pucci is Non-executive Director on the Board of
Mr Pucci holds an MBA from the University of Chicago and is a graduate
Universita Degli Studi Di Napoli in Naples, Italy. Mr Pucci is an
citizen and resides in Boston, MA, USA.
Mr Pucci holds no shares and no options in Algeta ASA and he has not worked
consultant for the Company.
Stein Holst Annexstad, Algeta's Chairman, said: "We are very pleased to
Hilde and Paolo to the Algeta Board. Between them, they have a
experience in the global pharma industry and particularly in the
commercial development of innovative targeted cancer therapies. We look
to the valuable contributions they will make to the further
development of Algeta. We would also like to thank Ingrid Wiik and Joe
who stepped down from the Board at the AGM, for their efforts and input
their respective periods with the Company."
Algeta is a company focused on developing novel targeted therapies for
with cancer based on its alpha-pharmaceutical platform. The
headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC,
Cambridge, MA performing commercial marketing operations in the US.
listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE